|
|
采用生物合成，经FPLC纯化，我们可为客户提供不同长度、不同来源的microRNA mimics，模拟细胞中成熟miRNA的高水平表达，供客户对miRNA的生物进程及其对体内细胞的调控进行深入研究。 用lipofectamine 2000将重组tRNA/miR-34a与化学合成的miR-34a mimics转染入A549细胞内，用MTT法检测A549细胞活力；Western blot法检测miR-34a对靶蛋白表达的抑制。 图1. tRNA/miR-34a显著抑制肿瘤生长 图2. 比较重组tRNA/miR-34a与miR-34a mimics对肿瘤细胞生长抑制及调节靶蛋白表达的功能 1) Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM, Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy, J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. 2) Joseph L. Jilek#, Ye Tian#, Ai-Ming Yu*, Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice, Drug Metab Dispos, 2017, 45 (5): 512-522. 3) Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Genetically engineered miR-34a prodrug suppresses orthotopic osteosarcoma tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep.2016, 6:26611. 4) Zhijian Duan and Ai-Ming Yu, Bioengineered non-coding RNA agent (BERA) in action, Bioengineered. 2016 Nov-Dec; 7(6): 411–417. 5) Wang WP, Ho PY, Li MM, Chen QX, Addepalli B, Tu MJ, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, DeVere White R, Lam KS, Yu AM. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 2015, 354(2):131-141 . 6) Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric miR-1291 biosynthesized efficiently in E. coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos. 2015, 43(7): 1129-1136. 7) Chen QX, Wang WP, Zeng S, Uroyama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res, 2015, 43(7): 3857-3869. 8) Yong Zhao,1,2 Mei-Juan Tu,2 Yi-Feng Yu,1 Wei-Peng Wang,2 Qiu-Xia Chen,2 Jing-Xin Qiu,3 Ai-Xi Yu,1 and Ai-Ming Yu2, Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth, Biochem Pharmacol. 2015 Dec 15; 98(4): 602–613. 9) Li MM, Wang WP, Wu WJ, Huang M, and Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos.2014, 42(11): 1791-1795. |
